Curemark CEO Joan Fallon To Moderate Autism Panel At CNS Leaders Forum

Conference will focus on novel drugs for neurodegenerative diseases

News provided by

Oct 23, 2012, 10:00 ET

RYE, N.Y., Oct. 23, 2012 /PRNewswire/ -- Curemark founder and CEO Dr. Joan Fallon will moderate a panel on neurodegeneration including sessions on autism and schizophrenia at the Phaciliate CNS Leaders Forum, to be held Nov. 5-7 in Boston at the Seaport Hotel. The forum will bring together senior R&D and business executives driving the development and launch of novel drugs for neurodegenerative diseases, psychiatric disorders and pain.

Curemark, a drug research and development company focused on the treatment of neurological diseases, has completed Phase III clinical trials for CM-AT, its autism treatment. The company announced that the study met its primary and secondary endpoints. Top line results demonstrated a statistically significant effect of CM-AT over placebo on both the core and non-core symptoms of autism, according to Curemark.

Dr. Fallon will provide the introduction and overview to the CNS Forum section on "Breakthroughs in the Re-categorization of Psychiatric Disorders," scheduled for Tuesday, November 6, at noon. Panel participants include Dr. Randall Carpenter, president and CEO, Seaside Therapeutics, Inc; Dr. Sonia Maria Poli, head of non-clinical development and interim head of CNS, Addex Pharmaceuticals, Ltd; David Bleakman, PhD, executive director and chief scientific officer, neuroscience discovery research, Eli Lilly and Company; and Frank S. Menniti, PhD, chief scientific officer, Mnemosyne Pharmaceuticals.

"I am very pleased to lead this workshop that will examine and discuss novel approaches to treating neurodegenerative disorders including schizophrenia and autism. The panel will discuss inventive and new strategies for examining subpopulations and genomic approaches to treatment," Fallon said. "Biomarkers, including physiological and gene markers, may ultimately lead to better and more efficient treatment for many of the neuropsychiatric disorders, which are presently treated as a single category of disease."

According to the latest estimates, autism affects 1 in 88 children and 1 in 54 boys in the United States. Schizophrenia affects approximately 1% of the U.S. population, according to the National Institute of Mental Health (NIMH).

About Curemark LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company announced in December, 2011, that its Phase III double blind randomized placebo controlled multicenter clinical trial of CM-AT for autism met its primary and secondary endpoints. To learn more about our innovative science, visit www.curemark.com.

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of the Curemark products CM-AT, CM-4612 and CM-182 their potential advantages, their potential for use in treating diseases or disorders, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning the Curemark products CM-AT, CM-4612 and CM-182. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of the Curemark products CM-AT, CM-4612 and CM-182, our ability to finance our development of CM-AT, CM-4612 and CM-182 regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.

SOURCE Curemark, LLC